In this segment, Dr. Charles J. Ryan asks Dr. Alan H. Bryce how clinicians balance the benefits of treatment intensification with the potential for added toxicity in patients with metastatic ...
In this video, Gordon A. Brown, DO, FACS, explores post hoc analyses from CAPItello-281 evaluating increasing PTEN deficiency thresholds and their relationship to treatment response. Understanding how ...
Dalia Kaakour, MD, MPH, highlights key findings from a retrospective review of cardiovascular system toxicities in patients initiating novel hormonal therapies for advanced prostate cancer. Kaakour is ...
FDA approved VYBRIQUE, an orally dissolving sildenafil film for erectile dysfunction in men ≥18 years, supported by a 12-week phase 3 trial showing significant benefit over placebo. Discreet, ...
FDA sNDAs seek approval of belzutifan plus lenvatinib for post–PD-1/PD-L1 advanced ccRCC, setting an October 4, 2026 PDUFA target action date. LITESPARK-011 randomized 747 patients to belzutifan 120 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results